North America to continue to lead the anti-epileptic drugs market -GMI Research

Global Aluminum Nickel Catalyst Market Opportunity Analysis (2016-2021)

The global Anti-Epileptic Drugs market was valued at USD 3,323.7 million in 2017 and is projected to reach USD 4,458.1 million by 2025, growing at a CAGR of 3.8% during 2018–2025. The major factors driving the anti-epileptic drugs market is the rising awareness about epilepsy, new drug approvals, and drug structure advancements in Anti-Epileptic Drugs industry are likely to drive the growth of the global Anti-Epileptic Drugs market in near future.

Furthermore, advancements in medication management and healthcare services with the increasing number of drug approvals across the globe have led to the burgeoning market growth of Anti-Epileptic Drugs market.

Valproic Acid drug segment is expected to dominate global Anti-Epileptic Drugs market during the forecast period. In 2017, about one-fourth of the market share was held by Valproic Acid drug in the component segment. However, the highest growth rate is expected to be witnessed by the Lacosamide component segment during the forecast period owing to the increase in usage in the treatment of partial-onset seizures.

Players are investing a lot in developing and introducing anti-epileptic drugs. For instance, On January 2017, Novartis drug Votubia got approval from EU. This drug will be used for the treatment of refractory partial-onset seizures in patients with TSC. Further, it is foreseen with the growing awareness about the disease and government initiatives the anti-epileptic drugs market will witness significant growth in the emerging markets of Asia-Pacific in the coming 4-5 years .”
—-GMI Research

Based on geography, North America held the largest share in the market in 2017 because of growing awareness about the disease and treatment available, increasing number of rehabs and surgical centers in the region and exponential increase in the epilepsy population. In addition, there has been a rise in the number of approved anti- epileptic drugs. Europe is the second largest region for Anti-Epileptic Drugs market and is expected to grow at a moderate rate during the forecast period.

Key takeaways:
• In 2017, the Valproic Acid drug type held about one-fourth of the market share.
• Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, and Valeant Pharmaceuticals are the leading players.
• Lacosamide drug type is anticipated to grow at the highest rate during the forecast period from 2018 to 2025.
• North America region occupied maximum revenue share in the global Anti-Epileptic Drugs market in 2017.

Some of the key players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The global Anti-Epileptic Drugs market has been segmented on the basis of spectrum type, the market comprises of Narrow and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide.

The research report “global Anti-Epileptic Drugs market” provides in-depth analysis of the Anti-Epileptic Drugs market, globally, based on spectrum type, drug type and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers propelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for Anti-Epileptic Drugs market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

For more details, browse the Table of Contents:
Early buyers will get customization upto 20% on report

Contact Sarah Nash
Tel: +353 1 536 3035
U.S Office +1 860 881 2270
Europe Office +353 1 442 8820